[{"id":"3f3f38dc-55ac-40c3-bcda-4271d98a6aef","acronym":"","url":"https://clinicaltrials.gov/study/NCT05168904","created_at":"2021-12-23T16:53:47.392Z","updated_at":"2024-07-02T16:35:20.258Z","phase":"Phase 1/2","brief_title":"A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT05168904","lead_sponsor":"Cyclacel Pharmaceuticals, Inc.","biomarkers":" BRAF • CDK9","pipe":"","alterations":" ","tags":["BRAF • CDK9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fadraciclib (CYC065)"],"overall_status":"Suspended","enrollment":" Enrollment 210","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-08"},{"id":"797d22d8-aa1c-4cc4-b44a-670a2d8ef7a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04983810","created_at":"2024-01-25T18:19:03.718Z","updated_at":"2024-07-02T16:35:22.250Z","phase":"Phase 1/2","brief_title":"A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma","source_id_and_acronym":"NCT04983810","lead_sponsor":"Cyclacel Pharmaceuticals, Inc.","biomarkers":" CDK9","pipe":"","alterations":" ","tags":["CDK9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fadraciclib (CYC065)"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 07/12/2021","start_date":" 07/12/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-01-25"}]